Loading...
The utility of radiotherapy is unclear in the management of metastatic prostate cancer with limited numbers of metastases, frequently referred to as oligometastatic cancer.
Investigators in the U.K and Switzerland have now conducted an industry-funded, multicenter, randomized, controlled phase III study (STAMPEDE) to investigate the potential benefit of adding radiotherapy to standard-of-care androgen-deprivation therapy (ADT) in 2061 men with newly diagnosed metastatic prostate cancer (median age, 68 years; median prostate-specific antigen level, 97 ng/mL). Of these patients, 54% had high metastatic burden (defined as ≥4 bone metastases, with ≥1 outside the vertebral bodies or pelvis; visceral metastases; or both), 40% had low metastatic bu…